Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of OAB (urgency, with or without urge incontinence, usually with frequency and nocturia) for ≥3 or more months.~* Patients may be included if they are on another OAB medication; however, patients must washout from other OAB medications for at least 7 days prior to receiving solifenacin succinate. Previous non-drug treatment of OAB is allowed if it has been established at least 4 weeks prior to study entry and is continued throughout the study.~Exclusion Criteria:~* -Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor~* Evidence of urinary tract infection; chronic inflammation such as interstitial cystitis and bladder stones~* Clinically significant outflow obstruction (benign prostatic hyperplasia)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).